{"id":"W2084415993","doi":"10.1097/jto.0b013e318220c93e","title":"Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Adverse effect; Lung cancer; Progression-free survival; Clinical endpoint; Internal medicine; Nausea; Surgery; Phases of clinical research; Urology; Gastroenterology; Oncology; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001947658,0.0001188082,0.0005564616,0.0002112814,0.00002102976,0.000002307007,0.00008709533,0.0000988319,0.0001512134],"category_scores_gemma":[0.00002996338,0.0000794456,0.00009464939,0.00017112,0.00004546593,0.0001042697,0.00001445862,0.0002394165,0.000001527159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003517009,"about_ca_system_score_gemma":0.001026986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006925489,"about_ca_topic_score_gemma":0.00007301908,"domain_scores_codex":[0.9988781,0.00006011565,0.000585905,0.0001184755,0.0001823176,0.0001751517],"domain_scores_gemma":[0.9985585,0.00005183725,0.0007666201,0.0001322569,0.0003652121,0.0001255477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4537165,0.02977918,0.1964113,0.0003680799,0.0008807276,0.0005294904,0.008499881,0.00008273053,0.001060867,0.00001014204,0.000609764,0.3080513],"study_design_scores_gemma":[0.634573,0.1254346,0.2151534,0.001180799,0.004519114,0.00006428395,0.001188278,0.00008200039,0.01168982,0.00007321598,0.005685679,0.0003557474],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994004,0.0003378043,0.0001324782,0.0001585569,0.0006919655,0.0006870578,0.00001401298,0.000003710663,0.003970449],"genre_scores_gemma":[0.9910256,0.0001266779,0.008275488,0.000119158,0.0001579148,0.00002574094,0.000005787812,0.00001769503,0.000245974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3076956,"threshold_uncertainty_score":0.3239698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02273317214820727,"score_gpt":0.434747771304466,"score_spread":0.4120145991562588,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}